Clinical Trials Logo

Anemia clinical trials

View clinical trials related to Anemia.

Filter by:

NCT ID: NCT05386264 Not yet recruiting - Aplastic Anemia Clinical Trials

Autologous Tregs for Aplastic Anaemia

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

This Phase I study will determine the safety and optimal dose of expanded autologous Tregs to treat patients with Aplastic Anaemia (AA) (who have failed, or are considered ineligible for IST (immunosuppressive therapy) / other treatments) using expanded autologous T regulatory cells (Tregs) from AA patients at King's College Hospital, that have been prepared at the licensed Good Manufacturing Practices (GMP) production facility at Guy's Hospital, London

NCT ID: NCT05384691 Not yet recruiting - Anemia Clinical Trials

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS), that are non-transfusion dependent

NCT ID: NCT05382065 Not yet recruiting - Anemia Clinical Trials

Anemia and Duration of Mechanical Ventilation

Start date: June 2022
Study type: Observational

In mechanically ventilated patients in intensive care unit, anemia is commonly seen and it is probably associated with adverse outcomes including mortality. We aim to investigate the impact of duration of anemia and the duration of mechanical ventilation as well as clinical outcomes in critically ill patients in intensive care unit who required ventilatory support >96 hr.

NCT ID: NCT05374837 Not yet recruiting - Anemia Clinical Trials

Mobile Messaging for Improved Nutrition

Start date: May 15, 2022
Phase: N/A
Study type: Interventional

This project will examine the impact of an infant and young child feeding (IYCF) voice messaging intervention delivered to mothers and fathers in Senegal on the consumption of a minimum acceptable diet and anemia prevalence in their children.

NCT ID: NCT05365308 Active, not recruiting - Clinical trials for Iron-deficiency Anemia

EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

The objective is to determine if a set of clinical supports that includes computer-assisted identification, an EHR registry, facilitated GI referral, and an EHR tool for documentation improves the timely referral and completion of bidirectional endoscopy in men aged 18 years and older and women aged 40 years and older with iron deficiency anemia.

NCT ID: NCT05358509 Recruiting - Clinical trials for Iron Deficiency Anemia

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

Start date: March 15, 2021
Phase: Phase 4
Study type: Interventional

Anemia is a worldwide problem with iron deficiency being the most common cause. When anemia occurs in pregnancy, it increases the risk of adverse maternal, fetal, and postnatal outcomes. Anemia rates are among the highest in South Asia, with a recent national survey indicating that over half of pregnant women in India are classified as anemic. For nearly 40 years, India's first-level treatment for anemia in pregnancy has been oral iron; however, side effects, poor adherence to tablet ingestion, and low therapeutic impact are among reasons to consider a new paradigm for treatment of pregnant women with iron deficiency anemia (IDA). Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial is a 3-arm, randomized-controlled trial designed to assess if a single dose of an intravenous (IV) iron formulation, administered early in the second trimester of pregnancy for treatment of moderate IDA, will result in a greater proportion of participants in the IV iron arms achieving a normal hemoglobin concentration in the third trimester when compared to participants randomized to receive oral iron. This trial is also designed to test the hypothesis that the low birth weight (LBW) rate for participants randomized to the IV iron arms will be lower when compared to the LBW rate of those randomly assigned to the oral iron arm. The three arms include two IV iron arms (arm 1 - ferric carboxymaltose, arm 2 - iron isomaltoside, also known as ferric derisomaltose) and an active, comparator arm receiving oral iron, which is the standard of care. This study will be conducted in two states in India - Karnataka and Rajasthan. This study supports the overall goals of the Indian Ministry of Health and Family Welfare for pregnancy care; thus, all study participants will be followed according to the Ministry's antenatal care guidelines, and data will be collected through 42 days post-delivery. (see attached protocol for more detail)

NCT ID: NCT05356325 Active, not recruiting - Anemia Clinical Trials

FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.

Start date: October 18, 2021
Study type: Observational [Patient Registry]

Anemia is associated with cardiovascular disease. Iron deficiency is usually induced in chronic kidney disease (CKD). In clinical studies, an inverse association between serum levels of iron and fibroblast growth factor 23 (FGF23), a cardiovascular risk factor, has been demonstrated. In addition, a number of the I.V. iron presentations mostly used to treat anemia show unwanted side effects related to phosphate alterations and increased FGF23. Objectives. The General Objective of this project is to evaluate, through in vivo and in vitro studies, the cardiovascular alterations related to the anemia-induced increase in FGF23 production; as well as the identification of possible molecular targets that may be useful in its prevention and/or palliation. Specific Objectives are: 1) To determine in a population with anemia (due to iron deficiency), with and without CKD, an association between the parameters related to iron metabolism, FGF23 and markers of cardiovascular damage. 2) To evaluate in vivo, in a murine experimental model of anemia, with and without CKD, the effects of the modulation (inhibition) of triggers of iron deficiency (hepcidin) and of the increase in FGF23 (HF1α), on markers of cardiovascular damage. 3) To compare in vivo, in an experimental model of anemia with and without CKD, the effect of different I.V. iron presentations (ferrous sulphate, ferric carboxymaltose and ferric citrate) on FGF23 levels and their cardiovascular impact. 4) To evaluate in vitro, in cardiomyocytes cultures, in the presence of iron deficiency, the direct effect of FGF23 on the induction of cardiac damage. 5) To evaluate in vitro, in osteoblasts cultures, the direct effect of ferrous sulphate, ferric carboxymaltose, ferric citrate and hepcidin. Methodology. The levels of intact and C-terminal FGF23 (FGF23i and FGF23c), the differential expression profile of plasma miRNAS and of proteomic, markers of cardiovascular disease, mineral metabolism, inflammation and oxidative stress and intracellular signalling pathways will be evaluated.

NCT ID: NCT05355324 Completed - Anemia Clinical Trials

Risk Factor for Readmission and Death of Lower Respiratory Infections in Older Adults

Start date: March 1, 2016
Study type: Observational

Lower respiratory tract infection(LRTI) is a prevalent disease that threatens the health of older people worldwide. Anemia is also a common disorder in the elderly, and its prevalence increases significantly with age. Most factors that contribute to the development of anemia are improvable. Therefore, we investigated whether anemia was a risk factor for LRTI-caused readmission and death in the elderly occurring within 1 year of discharge from the hospital.

NCT ID: NCT05323617 Not yet recruiting - Clinical trials for Severe Aplastic Anemia (SAA)

Efficacy of Romiplostim in Treatment of Severe Aplastic Anemia in Non-Asian Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Start date: July 31, 2022
Phase: Phase 2
Study type: Interventional

Romiplostim has been used in clinical trials for the treatment of severe aplastic anemia (SAA) in Asian participants who are either previously untreated with immunosuppressive therapy (IST) or refractory to IST. This study will evaluate the efficacy of romiplostim in the treatment of non-Asian participants with SAA. The primary objectives of this study are to: Arm 1: evaluate the efficacy of romiplostim and immunosuppressive therapy (IST) in adult non-Asian severe aplastic anemia (SAA) participants who are previously untreated with IST (1L) Arm 2: evaluate the efficacy of romiplostim treatment in adult non-Asian SAA participants who are refractory to IST (2L+)

NCT ID: NCT05320198 Not yet recruiting - Anemia Clinical Trials

Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.